Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) EBITDA (2021 - 2025)

Historic EBITDA for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$6.0 million.

  • Lyra Therapeutics' EBITDA rose 4949.78% to -$6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$33.0 million, marking a year-over-year increase of 6621.71%. This contributed to the annual value of -$93.5 million for FY2024, which is 4917.41% down from last year.
  • Latest data reveals that Lyra Therapeutics reported EBITDA of -$6.0 million as of Q3 2025, which was up 4949.78% from -$7.4 million recorded in Q2 2025.
  • Over the past 5 years, Lyra Therapeutics' EBITDA peaked at -$6.0 million during Q3 2025, and registered a low of -$48.2 million during Q2 2024.
  • Its 5-year average for EBITDA is -$14.6 million, with a median of -$13.6 million in 2021.
  • Per our database at Business Quant, Lyra Therapeutics' EBITDA tumbled by 20806.63% in 2024 and then skyrocketed by 8455.77% in 2025.
  • Quarter analysis of 5 years shows Lyra Therapeutics' EBITDA stood at -$13.6 million in 2021, then dropped by 4.47% to -$14.2 million in 2022, then dropped by 6.26% to -$15.1 million in 2023, then rose by 27.24% to -$11.0 million in 2024, then surged by 45.6% to -$6.0 million in 2025.
  • Its last three reported values are -$6.0 million in Q3 2025, -$7.4 million for Q2 2025, and -$8.5 million during Q1 2025.